Targeted drug trial offers hope for Tough-to-Treat prostate cancer
NCT ID NCT04631744
Summary
This study tested the drug cabozantinib in men with advanced prostate cancer that had spread and was no longer responding to standard hormone-blocking treatments. The goal was to see if the drug could slow the cancer's growth, especially in patients whose tumors had specific genetic changes or had spread to the liver. Participants took the drug daily until their cancer progressed or side effects became too severe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.